MaxCyte (MXCT) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Q1 2026 earnings: MaxCyte is scheduled to report results after the close on May 12, 2026, with analysts forecasting an EPS of ($0.10) and revenue of about $7.284 million.
• Recent results showed a mixed picture—MaxCyte beat EPS estimates last quarter (reported ($0.06) vs. ($0.08) expected) but missed revenue ($6.76M vs. $9.16M consensus), and analysts now model roughly $0 EPS for the current and next fiscal years.
• Shares traded around $0.83 (down 3.7%) with a market cap near $88M; analyst coverage is mixed (consensus "Hold" with a $5.50 target) and institutional investors own about 68.8% of the stock.

MaxCyte (NASDAQ:MXCT - Get Free Report) will likely be announcing its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $7.2840 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The firm had revenue of $6.76 million during the quarter, compared to the consensus estimate of $9.16 million. MaxCyte had a negative return on equity of 22.15% and a negative net margin of 135.14%. On average, analysts expect MaxCyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Trading Down 3.7%

Shares of MXCT traded down $0.03 during trading hours on Tuesday, reaching $0.83. 232,518 shares of the company's stock traded hands, compared to its average volume of 1,012,035. The stock has a market cap of $88.27 million, a PE ratio of -1.92 and a beta of 1.37. The firm's 50 day simple moving average is $0.79 and its 200-day simple moving average is $1.18. MaxCyte has a 12 month low of $0.64 and a 12 month high of $2.86.

Hedge Funds Weigh In On MaxCyte

Hedge funds and other institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. bought a new position in shares of MaxCyte during the second quarter valued at approximately $26,000. State of Wyoming bought a new stake in shares of MaxCyte during the second quarter valued at approximately $38,000. Jain Global LLC bought a new stake in MaxCyte in the 4th quarter worth approximately $45,000. BNP Paribas Financial Markets grew its position in MaxCyte by 266.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company's stock worth $57,000 after purchasing an additional 18,913 shares during the period. Finally, Virtu Financial LLC bought a new stake in MaxCyte in the 4th quarter worth approximately $67,000. Institutional investors own 68.81% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MXCT. Weiss Ratings reiterated a "sell (e+)" rating on shares of MaxCyte in a research report on Friday, April 24th. Wall Street Zen downgraded shares of MaxCyte from a "hold" rating to a "sell" rating in a report on Saturday, April 18th. Finally, Craig Hallum dropped their price objective on shares of MaxCyte from $7.00 to $5.00 and set a "buy" rating for the company in a report on Wednesday, March 25th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $5.50.

MaxCyte Company Profile

MaxCyte, Inc NASDAQ: MXCT is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company's instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.